This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
Application based on results from the TROPION-Breast01 Phase III trial
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Combination shows consistent benefit across prespecified post-progression outcomes
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Subscribe To Our Newsletter & Stay Updated
